Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Ginkgo Bioworks Holdings, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$8.07 |
52 Week High | US$82.80 |
52 Week Low | US$5.26 |
Beta | 1.07 |
11 Month Change | -0.98% |
3 Month Change | -28.94% |
1 Year Change | -88.34% |
33 Year Change | -98.43% |
5 Year Change | n/a |
Change since IPO | -98.01% |
Recent News & Updates
Ginkgo Bioworks: Here Comes The Test
Aug 22The Price Is Right For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Even After Diving 27%
Aug 16Recent updates
Ginkgo Bioworks: Here Comes The Test
Aug 22The Price Is Right For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Even After Diving 27%
Aug 16Ginkgo Bioworks: Losing A Major Supporter
Jun 25Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 47% Slump
Jun 18Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
May 11Ginkgo Bioworks: Broken Narrative
May 10Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
Apr 26Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts
Mar 06With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For
Mar 01Ginkgo Bioworks: More Awful Revenue Guidance
Mar 01Ginkgo Bioworks At The Intersection Of Cutting-Edge Technology And Financial Disappointment
Jan 26Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty
Dec 20Ginkgo Bioworks: A Long Way To Go
Nov 21News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat
Nov 13Ginkgo Bioworks: More Revenue Issues
Nov 13Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump
Nov 10Porter's 5 Forces Suggest That Ginkgo Is A Buy
Oct 25Ginkgo Bioworks: Products Progressing Towards Market
Oct 10Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)
Aug 30Ginkgo Bioworks: Lack Of Progress Is A Concern
Aug 18Ginkgo Bioworks: Major Revenue Trouble (Ratings Downgrade)
Aug 10Ginkgo Bioworks: Tremendous Potential, But Strong Short Term Headwinds
Jun 23Ginkgo Bioworks: Avoid For Now
Feb 20Ginkgo: Standardizing Offerings For Growth
Feb 08Ginkgo Bioworks: Increasing Focus On Pharma And Biotech
Jan 12Ginkgo Bioworks launches Ginkgo Enzyme Services
Dec 08Shareholder Returns
DNA | US Chemicals | US Market | |
---|---|---|---|
7D | 18.5% | 0.2% | 1.2% |
1Y | -88.3% | 14.1% | 30.2% |
Return vs Industry: DNA underperformed the US Chemicals industry which returned 14.1% over the past year.
Return vs Market: DNA underperformed the US Market which returned 30.2% over the past year.
Price Volatility
DNA volatility | |
---|---|
DNA Average Weekly Movement | 18.2% |
Chemicals Industry Average Movement | 6.0% |
Market Average Movement | 6.4% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DNA's share price has been volatile over the past 3 months.
Volatility Over Time: DNA's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 1,218 | Jason Kelly | www.ginkgobioworks.com |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Ginkgo Bioworks Holdings, Inc. Fundamentals Summary
DNA fundamental statistics | |
---|---|
Market cap | US$436.21m |
Earnings (TTM) | -US$897.68m |
Revenue (TTM) | US$184.34m |
2.4x
P/S Ratio-0.5x
P/E RatioIs DNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DNA income statement (TTM) | |
---|---|
Revenue | US$184.34m |
Cost of Revenue | US$36.46m |
Gross Profit | US$147.88m |
Other Expenses | US$1.05b |
Earnings | -US$897.68m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -16.11 |
Gross Margin | 80.22% |
Net Profit Margin | -486.98% |
Debt/Equity Ratio | 0% |
How did DNA perform over the long term?
See historical performance and comparison